Abstract
Intestinal diseases can share clinical symptoms and gut microbiome alterations, necessitating cross-disease comparisons and the use of multi-disease models. Here, we performed meta-analyses on fecal metagenomes of Crohn’s disease (CD), ulcerative colitis (UC) and colorectal cancer (CRC), and identified 65 marker species and 74 marker pathways that were significantly altered in >=2 studies of the same disease. We grouped marker species by their co-occurrences into disease-specific and mixed clusters according to whether all the cluster members belong to the same disease, and revealed their distinct phylogenetic relationships: species in disease-specific clusters are phylogenetically related, while those in mixed clusters are more distant; strikingly, UC- and CRC-specific species are phylogenetically closer than to CD-specific ones, likely because UC-patients have higher risk of CRC. Consistent to their phylogenetic relationships, marker species had similar within-cluster and different between-cluster metabolic preferences. In CD and CRC, most marker species correlated with an indicator of leaky gut, suggesting a link between gut dysbiosis and human derived contents. In fact, our results suggested that due to physio-metabolic alterations, the diseased gut may represent a stressed environment and pose stronger selection to gut microbes; consequently, marker species in diseases showed more coordinated changes than the controls. With the marker species and pathways, we constructed three high-performance (including multi-disease) models with AUROC of 0.88 and true positive rates up to 89%, and explained their putative clinical applications. Together, our results improved our understanding on the relationships among common intestinal diseases, and strongly support the feasibility of metagenome-based multi-disease diagnosis.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was partly supported by National Key Research and Development Program of China 2018YFC0910502 (to W.H.C.), National Natural Science Foundation of China (61932008, 61772368, 61572363), National Key R&D Program of China (2018YFC0910500), Natural Science Foundation of Shanghai (17ZR1445600), Shanghai Municipal Science and Technology Major Project (2018SHZDZX01) and ZJLab.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Emails: Puzi Jiang: puzjiang{at}hust.edu.cn
Sicheng Wu: wu_sicheng{at}hust.edu.cn
Xing-Ming Zhao: xmzhao{at}fudan.edu.cn
Wei-Hua Chen: weihuachen{at}hust.edu.cn
Data Availability
Correspondence and requests for materials should be addressed to W.H.C. and X.M.Z..